A DRF Study to Evaluate Safety, Tolerability, PK, and Activity of Oradoxel Monotherapy in Subjects w Adv. Malignancies

PHASE1UnknownINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 20, 2017

Primary Completion Date

March 30, 2020

Study Completion Date

April 30, 2020

Conditions

Solid Tumor

Interventions

DRUG

Oradoxel

oral docetaxel will be supplied in capsules and oral HM30181A-UK tablets

Trial Locations (3)

RECRUITING

Mayo Clinic, Rochester

RECRUITING

Cancer Therapy & Research Center at UTHSCSA, San Antonio

RECRUITING

Mayo Clinic, Phoenix